ASX:PNV PolyNovo (PNV) Stock Price, News & Analysis → How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad) Free PNV Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3.38 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield6.86%Price TargetN/A Stock AnalysisStock Analysis Get PolyNovo alerts: Email Address Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. About PolyNovo Stock (ASX:PNV)PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.Read More Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. PNV Stock News HeadlinesMarch 10, 2024 | msn.comImpediMed’s new leadership team looks to grow the companyMarch 8, 2024 | msn.comAustralia stocks higher at close of trade; S&P/ASX 200 up 1.07%April 25, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."March 3, 2024 | msn.comASX Health Stocks: Polynovo to get first orders in India; Clinuvel reports good results from Phase 2February 28, 2024 | fool.com.au3 ASX 200 shares just scored significant broker upgrades. Here's howFebruary 23, 2024 | fool.com.auWhy the PolyNovo share price has rocketed almost 200% higher in 12 monthsFebruary 19, 2024 | msn.comFundie Merchant Group picks four biotech stocks that could rip as sector hits rude health againFebruary 1, 2024 | au.finance.yahoo.comPolyNovo Limited (PNV.AX)April 25, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."January 26, 2024 | msn.comScoPo’s Powerplays: Nanosonics ‘in the doghouse’, but ASX health stocks are largely being good boysJanuary 22, 2024 | fool.com.auUp 10%: Why the Polynovo share price is popping todayJanuary 22, 2024 | finance.yahoo.comIs PolyNovo Limited (ASX:PNV) Potentially Undervalued?December 12, 2023 | fool.com.auWhy BlueScope, Fortescue, Polynovo, and Sigma shares are racing higherDecember 5, 2023 | msn.com16 top stocks inside these high-performing Aussie equities fundsNovember 21, 2023 | finance.yahoo.comPolyNovo (ASX:PNV) shareholders have earned a 21% CAGR over the last five yearsNovember 13, 2023 | reuters.comSpain's Sanchez wins support for PM bid amid anger over Catalan amnesty vowOctober 26, 2023 | finance.yahoo.comPolynovo Ltd (MFJ.SG)September 26, 2023 | morningstar.com.auAn undervalued opportunity among ASX shares added to our coverageSeptember 24, 2023 | fool.com.auPolynovo shares jump 12% on 'breathtaking' sales growthSeptember 13, 2023 | fool.com.auTrading near 52-week lows, are Polynovo shares too cheap to ignore?July 15, 2023 | ca.finance.yahoo.comPNV.AX - PolyNovo LimitedJuly 6, 2023 | msn.comAustralia stocks lower at close of trade; S&P/ASX 200 down 1.24%June 14, 2023 | finance.yahoo.comPolyNovo (ASX:PNV) pulls back 7.4% this week, but still delivers shareholders stellar 23% CAGR over 5 yearsJune 8, 2023 | msn.comWILSONS Maintains PolyNovo (ASX:PNV) Underweight RecommendationJune 8, 2023 | msn.comBELL POTTER SECURITIES Maintains PolyNovo (ASX:PNV) Buy RecommendationJune 7, 2023 | afr.comPolyNovo surges as sales advance to recordJune 6, 2023 | msn.comWhy is the Polynovo share price racing 14% higher today?See More Headlines Receive PNV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PolyNovo and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:PNV CUSIPN/A CIKN/A Webwww.polynovo.com.au Phone61 3 8681 4050FaxN/AEmployees237Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth2.63Net Income$1.59 million Net Margins1.91% Pretax MarginN/A Return on Equity2.42% Return on Assets-1.10% Debt Debt-to-Equity Ratio22.20 Current Ratio5.01 Quick Ratio1.58 Sales & Book Value Annual Sales$83.47 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow207.50 Book ValueA$0.10 per share Price / BookN/AMiscellaneous Outstanding Shares690,230,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.65 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Swami Raote BPHARMM.B.A., CEO & DirectorMr. Jan-Marcel Gielen C.A.CFO & Company SecretaryDr. David McQuillan Ph.D.Chief Technical & Scientific OfficerMr. Philip ScorgieChief Information OfficerMr. Ahmed HassanDirector of OperationsMs. Monica BenykDirector of PeopleDr. Tim MoorePrincipal ScientistMr. Edward GraubartPresident of North AmericaDr. Joseph F. Amaral M.D. (Age 68)Chief Medical Officer More ExecutivesKey Competitors4DMedicalASX:4DXAdheriumASX:ADRAinosNASDAQ:AIMDWAllegra Medical TechnologiesASX:AMTAnalyticaASX:ALTView All CompetitorsInsidersRobyn ElliottBought 32,000 shares on 10/31/2023Total: $38,080.00 ($1.19/share)Robyn ElliottBought 27,000 shares on 6/28/2023Total: $39,690.00 ($1.47/share)David WilliamsBought 14,453 shares on 6/7/2023Total: $23,442.77 ($1.62/share) PNV Stock Analysis - Frequently Asked Questions What other stocks do shareholders of PolyNovo own? Based on aggregate information from My MarketBeat watchlists, some companies that other PolyNovo investors own include Immutep (IMMP), Rural Funds Group (RFF), Vanguard FTSE Pacific ETF (VPL), UQM Technologies (UQM), Tesla (TSLA), Starpharma (SPL), Moelis Australia (MOE), iSignthis (ISX), Align Technology (ALGN) and Acasti Pharma (ACST). This page (ASX:PNV) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyNovo Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
